Posicionamento da Associação Brasileira de Alergia e Imunologia sobre o manejo da imunoterapia específica com alérgenos (ITA) em pacientes vacinados contra COVID‑19
Position statement of the Brazilian Association of Allergy and Immunology on the management of allergen-specific immunotherapy (AIT) in patients vaccinated against COVID‑19
Fernando Monteiro Aarestrup; Anna Caroline Nóbrega Machado Arruda; Clóvis Eduardo Santos Galvão; Gil Bardini Alves; Geórgia Véras de Araújo Gueiros Lira; Ernesto Akio Taketomi; Marcos Reis Gonçalves; Mariana Graça Couto Miziara; Sidney Souteban Maranhão Casado; Simone Valladão Curi; Veridiana Aun Rufino Pereira; Elaine Gagete
Resumo
A pandemia de COVID-19 representa um grande desafio para todas as especialidades médicas. A imunoterapia com alérgenos (ITA) é considerada o único procedimento terapêutico capaz de modificar a história natural das doenças alérgicas, e caracteriza o estado da arte na área de Alergia e Imunologia. Esta estratégia terapêutica de imunomodulação é capaz de promover a remissão e controle das doenças alérgicas por períodos prolongados, mesmo após o seu término. Existem poucos dados em relação ao emprego da ITA em pacientes vacinados contra COVID-19, e até o momento não há um posicionamento oficial das sociedades internacionais da área de Alergia e Imunologia Clínica. Este documento tem como objetivo estabelecer recomendações práticas para o manejo da ITA em pacientes que receberam a vacina contra COVID-19. Os fenômenos imunológicos envolvidos na imunoprofilaxia vacinal e no mecanismo de ação da ITA foram comparados, proporcionando o estabelecimento de recomendações precisas.
Palavras-chave
Abstract
The COVID-19 pandemic represents a serious challenge for all medical specialties. Allergen-specific immunotherapy (AIT) is considered the only therapeutic procedure capable of modifying the natural history of allergic diseases and characterizes the state of the art in the field of allergy and immunology. This therapeutic strategy of immunomodulation is able to promote remission and control of allergic diseases for prolonged periods, even after cessation. There are few data regarding use of AIT in patients vaccinated against COVID-19 and, to date, there is no official position statement published by international allergy and clinical immunology societies. This document aims to establish practical recommendations for the management of AIT in patients who have received the COVID-19 vaccine. The immunological mechanisms involved in immunoprophylaxis with vaccines and the mechanism of action of AIT have been compared to provide a solid basis for establishing precise recommendations.
Keywords
References
1. World Health Organization. WHO’s COVID-19 response [site na internet]. Disponível em: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline#.
2. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard [site na internet]. Disponível em: https://covid19.who.int/
3. Aarestrup FM. Imunopatologia da COVID-19 e suas implicações clínicas. Arq Asma Alerg Imunol. 2020;4(2):172-80.
4. Sharma O, Sultan AA, Ding H, Triggle CR. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Front Immunol. 2020;14,11:585354.
5. Izda V, Jeffries MA, SawalhaAH. COVID-19: A review of therapeutic strategies and vaccine candidates. Clin Immunol. 2021;222:108634.
6. American Academy of Allergy, Asthma and Immunology [site na internet]. Disponível em: https://www.aaaai.org/ask-the-expert/scit.Acessado em: 08/02/2021.
7. Klimek L, Jutel M, Akdis C, Bousquet J, Akdis M, Bachert C, et al. ARIA-MASK Study Group: Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement. Allergy. 2020;75(7):1546-54.
8. Dell'Edera A, Borghesan F, Favero E, Rattazzi M, Scarpa R, Tartaglia L, et al. Venom immunotherapy during COVID-19 pandemic: Experience fro a University Allergy Center in Northern Italy. World Allergy Organ J. 2020;13(12):100489.
9. Compalati E, Erlewyn-Lajeunesse M, Runa Ali F, Ojeda Fernández P, Garcia Nuñez I, Frati F, et al. Allergen Immunotherapy in the Era of SARS-CoV-2. J Investig Allergol Clin Immunol. 2020;30(6):459‑61.
10. Machado AS, Falcão ACAM, Serpa FS, Sano F, Rizzo JA, Elabras Filho J, et al. Recomendações da Associação Brasileira de Alergia e Imunologia para pacientes com Asma durante a COVID-19. Arq Asma Alerg Imunol. 2020;4(1):133-4.
11. Rosario Filho NA, Magalhães Rios JL, Morandi JLB, Tebyriçá JN, Lira GVGA, Antila MA, et al. Imunoterapia específica em época de pandemia de COVID-19. Arq Asma AlergImunol. 2020;4(2):238.
12. Klimek L, Pfaar O, Worm M, Bergmann KC, Bieber T, Buhl R, et al. Allergenimmunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA: Position paper of the German ARIA Group in cooperation with the Austrian ARIA Group, the Swiss ARIA Group, German Society for Applied Allergology (AEDA), German Society for Allergology and Clinical Immunology (DGAKI), Society for Pediatric Allergology (GPA) in cooperation with AG Clinical Immunology, Allergology and Environmental Medicine of the DGHNO-KHC and the European Academy of Allergy and Clinical Immunology (EAACI). Allergol Select. 2020 May 28;4:44-52.
13. Sociedade Brasileira de Imunizações [site na internet]. Disponível em: https://sbim.org.br. Acessado em: 08/02/2021.
14. Kleine-Tebbe J, Klimek L, Hamelmann E, Pfaar O, Taube C, Wagenmann, et al. Severe allergic reactions to the COVID-19 vaccine – statement and practical consequences. Allergol Select. 2021;5:26‑8.
15. Taketomi EA, Miranda JS, Cunha-Júnior JC, Silva DAO. Allergenspecific immunotherapy follow-up by measuring allergen-specificIgG as an objective parameter. In: Metodiev K (ed.). Immunotherapy. Rijeka: InTech, 2017. p.381-401. Disponível em: http://dx.doi.org/10.5772/66711.
Submitted date:
02/23/2021
Accepted date:
03/05/2021
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email